Novo study shows low-dose Cagrisema produced more weight loss than low-dose tirzepatide
Source ↗
👁 0
💬 0
Diabetes patients taking a low dose of Novo’s experimental drug Cagrisema lost more weight than those taking a low dose of Eli Lilly’s tirzepatide in a new study. Patients receiving 1 milligram of Cagrisema lost an average of 12.4 percent of their weight over 60 weeks, Danish pharmaceutical company Novo said. Those receiving 5 milligrams […]
Comments (0)